Innoviva Inc
Research Innoviva Inc (INVA) on Bullrun: market cap USD 1.54B, P/E 5.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerINVA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.54B
- P/E5.2
- Financial periodQ2 2026
- RevenueUSD 119.59M
- Net income-USD 83.42M
- Free cash flowUSD 51.54M
- Gross margin75.8%
Valuation Snapshot
latest market cap is USD 1.54B; P/E is 5.2.
Peer valuation comparison
Latest P/E is 5.16x versus a Healthcare sector median of 24.46x (78.9% below).
Latest P/E is 5.16x versus a United States median of 24.87x (79.3% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 411.33M | USD 271.17M | USD 195.80M | 74.8% | 3.3 | USD 550.94M | USD 257.73M | USD 1.17B |
| FY2024 | USD 358.71M | USD 23.39M | USD 188.42M | 82.6% | 0.36 | USD 304.96M | USD 448.34M | USD 691.16M |
| FY2023 | USD 310.46M | USD 179.72M | USD 140.65M | 79.2% | 2.2 | USD 193.51M | USD 446.23M | USD 674.96M |
| FY2022 | USD 331.34M | USD 220.26M | USD 201.66M | n/a | 2.37 | USD 291.05M | USD 540.37M | USD 565.79M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.54B | 5.2 | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.49B | 6.5 | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.09B | 82.6 | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.03B | 36.5 | n/a | n/a |
| 2022 | 2022-12-30 | USD 924.63M | 4.2 | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.20B | 6.3 | n/a | n/a |
About Innoviva Inc
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Innoviva Inc's market cap?
Innoviva Inc's market capitalization is USD 1.54B.
What is Innoviva Inc's P/E ratio?
Innoviva Inc's price-to-earnings (P/E) ratio is 5.2.
What does Innoviva Inc do?
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI.